TP53 and B-cell chronic lymphocytic leukemia: Targeting of CLL with del (11q) and ATM mutation was also proven to be more effective with BCR or PARP inhibitors, thus further supporting that direct targeting of both TP53 and ATM is favorable in CLL aberration (Quijada-Álamo et al., 2020).